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Genetic variation in the HLA region is associated
with susceptibility to herpes zoster
DR Crosslin1,2, DS Carrell3, A Burt1, DS Kim1,2, JG Underwood2, DS Hanna2, BA Comstock4, E Baldwin3, M de Andrade5,
IJ Kullo6, G Tromp7, H Kuivaniemi7, KM Borthwick7, CA McCarty8,9, PL Peissig9, KF Doheny10, E Pugh10, A Kho11,
J Pacheco11, MG Hayes12, MD Ritchie13, SS Verma13, G Armstrong13, S Stallings14, JC Denny14, RJ Carroll14, DC Crawford15,16,
PK Crane17, S Mukherjee17, E Bottinger18, R Li19, B Keating20, DB Mirel21, CS Carlson22, JB Harley23, EB Larson3 and
GP Jarvik1,2
Herpes zoster, commonly referred to as shingles, is caused by the varicella zoster virus (VZV). VZV initially manifests as chicken pox,
most commonly in childhood, can remain asymptomatically latent in nerve tissues for many years and often re-emerges as shingles.
Although reactivation may be related to immune suppression, aging and female sex, most inter-individual variability in re-
emergence risk has not been explained to date. We performed a genome-wide association analyses in 22 981 participants (2280
shingles cases) from the electronic Medical Records and Genomics Network. Using Cox survival and logistic regression, we
identified a genomic region in the combined and European ancestry groups that has an age of onset effect reaching genome-wide
significance (P41.0 × 10− 8). This region tags the non-coding gene HCP5 (HLA Complex P5) in the major histocompatibility complex.
This gene is an endogenous retrovirus and likely influences viral activity through regulatory functions. Variants in this genetic
region are known to be associated with delay in development of AIDS in people infected by HIV. Our study provides further
suggestion that this region may have a critical role in viral suppression and could potentially harbor a clinically actionable variant
for the shingles vaccine.
Genes and Immunity (2015) 16, 1–7; doi:10.1038/gene.2014.51; published online 9 October 2014
INTRODUCTION
Herpes zoster is a significant, growing disease with a particular
burden to the aging US population. There are more than a
million cases of herpes zoster in the United States each year,
with an annual rate of 3–4 cases per 1000 person, with the
incidence increasing.1,2 Up to 3% of patients with herpes
zoster require hospitalization.1 The risk is higher for women,
persons of European ancestry compared with African
ancestry, and persons with a family history of herpes zoster.1,3
Annual US costs of incident herpes zoster infections are $1.1
billion.4
Clinically, herpes zoster presents as painful, usually unilateral,
vesicular skin infection that follows a dermatomal distribution.
Of those affected with herpes zoster and depending on age,
10–50% will be left with chronic postherpetic neuralgia.1
In addition, herpes zoster has recently been shown to be a risk
factor for cerebrovascular disease and myocardial infarction in a
retrospective cohort study 106 601 herpes zoster cases and
213 202 control in the United Kingdom.5
Although a vaccine is now available, it is only 50% effective and
currently is under-utilized. The herpes zoster vaccine is recom-
mended for people aged ⩾ 60 years, by the Centers for Disease
Control’s Advisory Committee on Immunization Practices, as two-
thirds of herpes zoster cases occur in people who are 460 years.
The vaccine is Food and Drug Administration (FDA) approved for
patients aged 450 years who have not experienced the disease.
Human herpes viruses, including the varicella zoster virus (VZV),
are likely to have a long evolutionary history and coevolved with
Homo sapiens.6 Thus host defenses have likely co-evolved with
herpes viruses. Viral infections are generally recognized only when
they cause symptomatic disease as viral activity within a host
often does not result in any clinical symptoms.6 The major risk
factor for clinical symptoms of herpes zoster is increasing age.1,6
T-cell immunity decreases with advancing age, which correlates
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with increased risk of clinical symptoms of herpes zoster.1 Genetic
polymorphisms of immune system genes, in particular, may
impact viral latency. Understanding what regulates the level of
viral productivity, and the resulting immune response, may lead to
clinical strategies to prevent or treat clinical disease.6
We performed a joint and genetic ancestry-stratified genome-
wide association analyses to identify common genetic variants
associated with herpes zoster diagnoses extracted from electronic
medical records (EMRs) in adult participants from the electronic
Medical Records and Genomics (eMERGE) Network. The Network is
a National Human Genome Research Institute-funded consortium
engaged in the development of methods and best practices for
using the EMRs as tools for genomic research.7,8 The Network
comprises a multi-ethnic cohort of roughly 57 000 individuals
linked to EMRs for phenotype mining from nine participating sites
(seven adult; two pediatric) in the United States.7
RESULTS
Demographics by case–control status
We provide the demographic measures of the eMERGE cohort by
case–control status and overall (Table 1). Out of the 22 981
participants eligible for these analyses, 2280 participants (~10%)
were categorized as herpes zoster cases. The breakdown of
participants by site is outlined. Geisinger Health System, Group
Health Research Institute (GHRI)/University of Washington, Mayo
Clinic and Marshfield Clinic cohorts were primarily comprised of
participants of European ancestry and were enriched for older
participants. Both the Northwestern University and Vanderbilt
University cohorts tended to include younger participants and
more patients of African ancestry compared to the other eMERGE
sites. The Icahn School of Medicine Mount Sinai sample was also
younger and has higher representation of Hispanic participants, in
addition to representation of African and European ancestry. As
expected, females were over-represented in cases (61%) as
compared with controls (55%). Cases had a lower median body
mass index (BMI; 27.9 kg m− 2) than controls (28.8 kg m− 2).
Censored age, defined as onset age for cases and last observed
BMI age for controls, was well matched. We also delineate the
breakdown of genetically determined ancestry by case–control
status (Table 1). There were a higher proportion of European
ancestry participants in the case group (88%) as compared with
the controls (79%), as expected. Conversely, there are fewer
African ancestry participants in the case group (8%) compared
with the controls (16%). Both the case and control groups
comprise 2% Hispanic. There is a slight case–control difference for
history of herpes simplex in case versus control (5% versus 2%,
respectively) and chemotherapy 41 year prior to censored age
(7% in cases vs 6% in controls) in this sample.
Genome-wide association study
We provide the association results for herpes zoster association
analyses stratified by genetically determined ancestry (Table 2).
This included Cox regression analyses in the joint and European
ancestry groups, as well as logistic regression analyses. Both the
Cox and logistic regression models suggested a strong association
on chromosome 6 in the human leukocyte antigen (HLA) region,
specifically tagging HLA Complex P5 (HCP5) and upstream
HLA-B in the beta block of the class 1 region (Figures 1 and 2,
respectively).
The variants driving the association in the European ancestry
group and tagging HCP5 were rs116062713 (P= 1.04 × 10− 7) and
rs114864815 (P= 6.94 × 10− 8) located upstream and at the 5′
untranslated region of HCP5, respectively. In each case, the minor
allele frequency ((MAF) = 0.08) conferred protection, with hazard
ratios (HR) = 0.73 (95% confidence interval (CI): 0.64–0.82). In the
joint ancestry survival analyses, these variants nearly reached
genome-wide significance (P= 5.22 × 10− 8 and 4.54 × 10− 8), with
HR~ 0.72 (95% CI: 0.65–0.82). With logistic regression analyses,
both the joint and European ancestry analyses yielded associa-
tions in this region, with P~ 4.00x10− 6 and odds ratio (OR) ~ 0.74
(95% CI: ~ 0.65–0.83). Manhattan plots and corresponding QQ
plots are provided (Supplementary Figures S1–S3, respectively).
We illustrate the regional linkage disequilibrium (LD) plot using
annotated P-values from the Cox regression analysis in the
European ancestry sample (Figure 3). LD, with respect to
rs114864815, was generated using the same European ancestry
sample and is annotated with shades of red. The background
recombination rate illustrated in blue was generated from the
1000 Genomes Pilot 1 data. There is a region in high LD with the
HCP5 variants upstream of HLA-B that yielded the most significant
association results in the European ancestry survival analyses
(Figure 3). The most significant single-nucleotide polymorphisms
(SNPs) (rs114045064 and rs112660930) reached genome-wide
significance (P= 5.06 × 10− 9 and 5.26 × 10− 9), with HR= 0.77 (95%
CI: 0.71–0.85). These SNPs are tagging a repeated untranslated
region region of the retrogene of dihydrofolate reductase (DHFR)
gene. With respect to logistic regression analyses, both the joint
and European ancestry analyses yielded associations in this
region, with P~ 1.00 × 10− 7 and OR~ 0.80 (95% CI: ~ 0.73–0.87).
None of these variants reached genome-wide significance in the
African ancestry and Hispanic groups (Table 2).
We provide a dot plot illustrating median age of zoster onset
for case subjects of genetically determined European ancestry
by the SNPs associated with herpes zoster, as compared
with the overall median of 67.96 (Supplementary Figure S4).
Each SNP in the HCP5 region is categorized as having 0, versus 1 or
2 copies of the minor allele. For each of these SNPs, having
one or two copies of the minor allele was associated with a later
median age of herpes zoster onset, as compared with the
major allele.
Table 1. Summary statistics of demographic data and phenotypes by
eMERGE participating site and combined
Case Control Overall
N 2280 20 701 22 981
Site
Geisinger 10% (222) 13% (2696) 13% (2918)
Group Health/
UW
25% (572) 12% (2475) 13% (3047)
Mayo Clinic 13% (291) 22% (4523) 21% (4814)
Marshfield 32% (720) 12% (2543) 14% (3263)
Mt Sinai 7% (157) 15% (3095) 14% (3252)
Northwestern 6% (127) 10% (1974) 9% (2101)
Vanderbilt 8% (191) 16% (3395) 16% (3586)
Sex (female) 61% (1 387) 55% (11 443) 56% (12 830)
Median BMI
(kgm− 2)
24.7, 27.9, 31.7 25.2, 28.8, 33.6 25.1, 28.7, 33.4
Censored age 57, 67, 77 56, 66, 77 56, 66, 77
Ancestry
African 8% (173) 16% (3312) 15% (3485)
European 88% (2 016) 79% (16 407) 80% (18 423)
Hispanic 2% (41) 2% (580) 2% (621)
H. simplex (yes) 5% (103) 2% (377) 2% (480)
Chemotherapy
(yes)
7% (164) 6% (1213) 6% (1377)
Abbreviations: BMI, body mass index; eMERGE, electronic Medical Records
and Genomics. The three numbers for BMI and age represent quartiles of
the distributions (25th, 50th and 75th).
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PheWAS (phenotype-wide association study)
We have included the top PheWAS associations (Po0.01) for two
SNPs associated with zoster (rs114864815 and rs114045064) with
respective International Classification of Diseases (ICD)-9 code, the
description of the phenotype, ß, OR, standard error, P-value, the
number of cases and controls and MAF (Supplementary Table S1).
The list was enriched in two general areas, including inflammatory
and inflammatory disorders or infections, and cancers of the skin
Table 2. Summary of effects of loci that reached genome-wide significance for the joint (n= 22 981, survival= 25 986) and European ancestry
(n= 18 423, survival= 22 679) analyses
Chr SNP A BP Joint MAF Cox Joint Cox European Logistic Joint Logistic European Gene Function
P-value P-value P-value (MAF) P-value (MAF)
HR (95% CI) HR (95% CI) OR (95% CI) OR (95% CI)
6 rs114045064 C 31332239 0.18 2.75× 10− 7 5.06 × 10− 9 6.70× 10− 6 (17.51) 2.24× 10− 8 (17.14) HLA-B Upstream
0.81 (0.75–0.88) 0.77 (0.71–0.85) 0.82 (0.75–0.89) 0.78 (0.71–0.85)
6 rs112660930 T 31332078 0.18 3.01× 10− 7 5.26 × 10− 9 7.69× 10− 6 (17.57) 2.56× 10− 7 (17.16) HLA-B Upstream
0.81 (0.75–0.88) 0.77 (0.71–0.85) 0.82 (0.75–0.89) 0.78 (0.71–0.86)
6 rs116062713 C 31433566 0.08 5.22× 10− 8 1.04 × 10− 7 1.75 × 10− 6 (7.82) 5.52 × 10− 6 (9.07) HCP5 Upstream
0.72 (0.65–0.82) 0.73 (0.64–0.82) 0.73 (0.65–0.83) 0.74 (0.65–0.84)
6 rs114864815 T 31428987 0.08 4.54× 10− 8 6.94 × 10− 8 1.19 × 10− 6 (7.69) 3.68 × 10− 6 (9.14) HCP5 3′ UTR
0.73 (0.65–0.82) 0.73 (0.64–0.82) 0.73 (0.65–0.83) 0.74 (0.65–0.84)
SNP Logistic African Logistic Hispanic HapMap pilot 1 low coverage
panel MAF
P-value (MAF) OR (95% CI) P-value (MAF) OR (95% CI) I2Heterogeneity index CEU YRI CHB+JPT
rs114045064 1.87 × 10− 1 (0.18) 8.26 × 10− 1 (0.26) 79.74 0.23 0.15 0.03
1.20 (0.92–1.57) 1.06 (0.63–1.78)
rs112660930 1.77 × 10− 1 (0.18) 8.33 × 10− 1 (0.26) 79.99 0.23 0.13 NA
1.20 (0.92–1.58) 1.06 (0.63–1.77)
rs116062713 NA (0.02) NA (0.04) NA 0.16 NA NA
NA NA (NA)
rs114864815 NA (0.01) NA (0.04) NA 0.16 NA NA
NA (NA) NA (NA)
Abbreviations: BP, base pair; CI, confidence interval; HCP5, HLA Complex P5; HR, hazards ratio; MAF, minor allele frequency; NA, not available; OR, odds ratio;
SNP, single-nucleotide polymorphism; UTR, untranslated region. The African ancestry and Hispanic analyses included 3460 and 584 participants, respectively.
Actual numbers for the analyses may be different due to missing phenotype and/or covariate data. The BP positions are defined from the GRCh37/hg19 build.
Both rs116062713 and rs114864815 did not meet the MAF threshold for the African ancestry and Hispanic analyses. The HapMap abbreviations are defined as
follows: (1) CEPH (Utah residents with ancestry from northern and western Europe) (abbreviation: CEU); (2) Yoruba in Ibadan, Nigeria (abbreviation: YRI); and
(3) Han Chinese in Beijing, China (abbreviation: CHB); and Japanese in Tokyo, Japan (abbreviation: JPT). For HapMap allele frequencies, each SNP was merged
into the corresponding variant: (1) rs114045064 was merged into rs2596551; (2) rs112660930 was merged into rs2596550; and (3) rs116062713 was merged
into rs75640364; and rs114864815 was merged into rs77349273.
Figure 1. Manhattan plot of P-values generated using Cox regression analysis in the joint ancestry sample.
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and mucosal areas. All of the association results are illustrated in a
PheWAS association plot (Supplementary Figure S5). Phenotypes
are grouped along the x axis by categorization within the PheWAS
code hierarchy.9,10
The strongest association in the PheWAS was herpes zoster with
P= 1.54 × 10− 5 and 1.57 × 10− 7 and OR= 0.73 and 0.75 with
rs114864815 and rs114045064, respectively. There were also many
inflammatory disorders or infections among the top associations
with the same variants: (1) Acute pancreatitis (P= 2.24 × 10− 3 and
1.69 × 10− 2); (2) Acute tonsillitis (P= 1.51 × 10− 3 and 4.48 × 10− 3);
(3) Cerebral atherosclerosis (P= 2.10 × 10− 3 and 5.29 × 10− 3);
(4) Vaginitis and vulvovaginitis (rs114045064, P= 2.70 × 10− 3); (5)
Impetigo (rs114045064, P= 2.99 × 10− 3); (6) Peptic ulcer
(rs114045064, P= 3.63 × 10− 3); (7) Meningitis (P= 3.87x10− 3 and
6.22x10− 3); (8) Acute bronchitis and bronchiolitis (P= 6.12x10− 3
and 4.23 × 10− 3); (9) Lichen planus (rs114045064; P= 4.80 × 10− 3);
(10) Acute pharyngitis (rs114045064; P= 6.39 × 10− 3); and (11)
Dyshidrosis (rs114045064; P= 9.51 × 10− 3).
There were was also an enrichment of cancers of the skin and
mucosal areas among the top associations with rs114864815 and
rs114045064, respectively: (1) Malignant neoplasm of oral cavity
and pharynx (rs114864815; P= 3.78 × 10− 3); (2) Cancer of nasal
cavities (rs114045064; P= 3.82 × 10− 3); (3) Carcinoma in situ of skin
(rs114864815; P= 4.12 × 10− 3); and (4) Non-melanoma skin cancer
(P= 5.38 × 10− 3 and 6.34 × 10− 3). Although not meeting the
Po0.01 threshold, an association with herpes simplex was
suggestive (rs114864815, rs114045064; P= 8.31 × 10− 2 and
1.69 × 10− 2). Distributions of P-values by PheWAS category based
on the associations for both rs114864815 and rs114045064 are
illustrated using box-and-whisker plots (Supplementary Figure S6).
Figure 2. Manhattan plot of P-values generated using Cox regression analysis in the European ancestry sample.
Figure 3. Regional LD plot using the SNP Annotation and Proxy Search software.25
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DISCUSSION
We were able to ascertain a robust herpes zoster phenotype from
EMR data using an electronic phenotyping algorithm. We found
strong evidence for protective variants in HCP5 among partici-
pants of the European ancestry. Our results suggest that genomic
variation in the HLA region may be associated with resistance to
herpes zoster. The major histocompatibility complex in humans, or
HLA system, is an excellent candidate region for assessing such
polymorphisms with its large number of immune-related genes.
The same variants implicated here for herpes zoster risk have been
shown to have a role in the progression of host HIV infection.11
Given the fact that HCP5 is non-coding and is related to human
endogenous retroviruses, we hypothesize that this region could
be serving a host-driven regulatory function for herpes zoster.
Herpes viruses are large (100–200 nm) and contain double-
stranded DNA, which also contain a large number of non-coding
RNAs that serve various regulatory functions.6 Associations in non-
coding regions such as HCP5 support the notion that genomic
variation of regulatory functions can be associated with risk of
viral reactivation.
Consistent with previous literature,1,3 we found associations
between female sex, European ancestry and older ages with
herpes zoster. Evaluation of age of onset effects suggests that
these variants influence age of onset of herpes zoster, which we
have demonstrated in the case participants of European ancestry
(Supplementary Figure S4).
There are several limitations to this study. Our sample sizes of
participants with herpes zoster for both African ancestry (n= 173)
and Hispanic (n= 41) are too small for ancestry-specific genomic
association studies. We also do not have information on whether
controls had initial exposure to VZV. The chickenpox vaccine
became available in the United States in 1995. Thus the vast
majority of our controls would not have been vaccinated for
chickenpox. More than 95% of the US adults experienced VZV
(usually as children) before the FDA’s licensure of the varicella
vaccine.12 Controls who never had primary infection with VZV are
not at risk of reactivation in the form of herpes zoster and could
reduce our power but should not lead to false-positive genetic
associations. However, we also cannot distinguish between a
protection from a primary VZV infection, extended VZV latency
and protection from re-emergence. Any or all of these factors
would lead to reduced risk of a clinical diagnosis of herpes zoster.
We do not know that the age of shingles diagnosis for cases was
their first episode of herpes zoster, and some controls may have
had herpes zoster that was not captured in the electronic health
record; however, both of these occurrences would typically bias
effect size towards the null. Finally, these results have not yet been
replicated, although this region’s role in the progression of host
HIV infection is in strong support of viral control. Future evaluation
should test the validity of this association.
The PheWAS results were encouraging for multiple reasons. We
were able to reproduce our original herpes zoster association
results using only ICD-9 codes to identify cases. Both the PheWAS
and the primary logistic/Cox regression phenotypes were
dichotomous phenotypes and relied on ICD-9 codes to define
cases and controls. However, there are differences in the analyses,
with the PheWAS being less detailed. The primary analysis
phenotype definitions included consideration of ICD-9 miscoding
(Methods) and other possible confounding effects, such as zoster
vaccination, chemotherapy and prior infections. Participants also
had to be ⩾ 40 years and have continual health system enrollment
prior to diagnosis. The PheWAS model adjusted for decade of
birth, sex, eMERGE study site and the first three principal
components (eigenvectors) from a combined ancestry principal
component analyses (PCA). For the logistic/Cox regression models,
sex, log10 median BMI, study site and eigenvectors 1 and 2 both
for joint and genetic ancestry-stratified groups were utilized as
covariates. The results also highlighted HLA genotype associations
with an enrichment of inflammatory and inflammatory disorders
or infections, thus supporting this region’s vital role in immune
response. Some of these HLA associations, such as the acute
pancreatitis, have been demonstrated before.13 We were also able
to demonstrate a suggestive association of SNPs associated with
zoster with herpes simplex. This is plausible, because VZV and
herpes simplex are ancestrally related.14 We did remove
participants with a history of herpes simplex for the European
survival analyses, and the results did not change (data not shown).
The top PheWAS associations were also enriched for phenotypes
with cancers of the skin and mucosal areas, which may also have
an infectious link.
In conclusion, we identified HCP5 SNPs that predict risk of
herpes zoster diagnosis and age of onset of the disease.
Participants with rs114864815 are at less risk and are affected at
later ages. We also identified variants that predict risk of herpes
zoster near the retrogene DHFR (upstream HLA-B). Inhibitors of
DHFR have been shown to potentiate the antiviral effects of
acyclovir on herpes viruses.15 It is unclear whether variation in one
or both of these gene regions are causal with onset of herpes
zoster or is a surrogate in strong LD with the true causal variant.
Further evaluation of this region will elucidate its function and its
association with the susceptibility of herpes zoster. This region is
also an excellent candidate for cerebrovascular disease and early
onset myocardial infarction as demonstrated in the retrospective
cohort study in the United Kingdom where herpes zoster was
shown to be a risk factor.5 The mining of EMRs for phenotypes
such as herpes zoster are providing unique opportunities for
discovery that normally would not be possible with traditional
genotype association studies. This field is relatively young, and in
many cases, like these results, all available data are utilized and
replication is not possible. As the field matures, and more bio-
repositories linked to EMRs come on line, replication data will be
available.
METHODS
Selection and description of participants in eMERGE
We developed an algorithm to extract individuals with herpes zoster from
the EMR while removing participants with significant comorbidities to
assess genetic association. This algorithm was designed at the University of
Washington and developed and implemented at the GHRI, both in Seattle,
WA, USA. To enhance our covariate data, we augmented traditional EMR-
based structured data (for example, diagnosis and procedure codes, labs
and medication records) with medication information extracted from
unstructured clinical notes (for example, progress notes and hospital
discharge summaries) using Natural Language Processing.16–18 Natural
Language Processing-derived information provides richer and more
complete information on medication exposures as many medications are
only referenced in clinical notes.
Briefly, cases were identified if participants were aged ⩾ 40 years with at
least one diagnosis code for herpes zoster and at least 1 year of continuous
health system enrollment prior to diagnosis. Suppression of the immune
system, whether by disease or by immunosuppressant drugs, is a major
risk factor for herpes zoster and was considered as an exclusion.
Exclusionary criteria included any of the following: (1) Vaccination for
herpes zoster within the last year for cases and ever for controls; (2) Two or
more diagnosis codes for HIV; (3) Cancer of the blood or bone marrow up
to 12 months prior to the index date; (4) Chemotherapy up to 12 months
prior to the diagnosis date; (5) Steroid use 21 days prior to index date; and
(6) History of transplant immunosuppression medications at any strength.
Controls were selected if they were never vaccinated for VZV (except for
survival analyses, see below), had no evidence of diagnosis codes for
herpes zoster and they did not have an above listed exclusion.
As a standard best practice in eMERGE, manual chart validation was
performed at two separate sites to ensure the phenotype data-mining
algorithm performed appropriately. To ensure the herpes zoster EMR
algorithm correctly classified participants, 25 cases and 25 controls were
randomly selected at both GHRI and Vanderbilt University, respectively (n
total = 100). At GHRI, there was a positive predicted value of 100% for the
HCP5 and herpes zoster
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cases and 96% for the controls. At Vanderbilt University, the positive
predicted value was 96, and 100% for the cases and controls, respectively.
eMERGE investigators have developed Phenotype KnowledgeBase
(PheKB), a repository for phenotype creation, validation and execution of
phenotype algorithms across the network and beyond.7,19 This tool was
utilized for the herpes zoster EMR algorithm to facilitate development and
revising of the phenotype. The algorithm and implementation data are
available on PheKB (Web Resources).
Genotyping and imputation
The eMERGE Coordinating Center (CC) at the Pennsylvania State University
(PSU) performed genotype imputations for the eMERGE Phase-II project,
which includes all participants’ samples from eMERGE-I and eMERGE-II,
using the BEAGLE software package (Version 3.3.1, Seattle, WA, USA).20
Details of the genotyping platforms for the nine eMERGE sites (seven adult
sites and two pediatric) can be found on the PSU eMERGE CC web site
(Web Resources). The majority of samples were genotyped on the Human
660 Quad, with additional samples genotyped by the OmniExpress chip
and others. Imputation was performed for all autosomes, with a reference
panel selected from the 1000 Genomes Project (October 2012 release). For
the analyses presented here, variants were included if the allelic R2⩾ 0.7,
call rate was ⩾ 99% and MAF was 40.03. The allelic R2 is the accuracy of
imputed genotypes in terms of the squared correlation between the allele
dosage (number of minor alleles) of the most likely imputed genotype and
the allele dosage of the true genotype.20 Further quality control/quality
assurance measures are outlined in the imputation guide provided on the
PSU eMERGE CC website (Web Resources).
Defining genetically determined ancestry
PCA were performed using the SNPRelate R statistical computing
package.21 Prior to inclusion into the correlation matrix, postimputation
variants were selected after LD pruning at r= 0.5 and a MAF40.03. For all
38 250 participants, genetically determined European ancestry was
assigned to all participants with eigenvectors 1 and 2 values within 4 s.
d. from the medians of eigenvectors 1 and 2 of self-identified European
ancestry participants. For genetically determined African ancestry, we
identified all participants with values within 2 s.d. from the medians of
eigenvector 1 and 2 of self-identified African ancestry participants. For
the Hispanic group, we identified all participants with values within 1 s.d.
from the medians of eigenvector 1 and 2 of self-identified Hispanic
participants.22 The ancestry classifications clustered with the genotyped
HapMap reference samples as we have recently published.23 Summaries
regarding genetically determined ancestry are listed (Table 1). To control
for ancestry-specific admixture, PCA was performed within each respective
ancestry group. This included 18 423 participants of European ancestry,
3485 of African ancestry and 621 Hispanic.
Association analyses
Our primary aim was to robustly identify variants associated with herpes
zoster diagnosis. Because age is a major risk factor for shingles, we
assessed survival using Cox proportional hazard analysis with end points of
age at loss to follow-up, death or VZV vaccination for controls, versus age
at first zoster episode for cases. When age of onset is variable and early
onset may indicate an increased genetic susceptibility, Cox regression may
have more statistical power than logistic regression.24 We used the coxph R
function with the base survival package in R for Cox proportional-hazards
regression analyses. We implemented this function using the R-plugin
feature in PLINK.25 For variables with repeated measures considered for
covariates (BMI and age at a given participant visit), median values were
utilized in the association models.
We performed a joint analysis of all participants and genetic ancestry-
stratified analyses of each ancestry group separately. For the joint analysis,
we included covariates for sex, log10 median BMI, study site and
eigenvectors 1 and 2. For the European ancestry analyses, eigenvectors
1 and 2 derived from the joint ancestry analysis were dropped from the
model and replaced with eigenvectors 1 and 2 derived from the European-
specific PCA analyses. SNP genotypes were coded as 0, 1 and 2 copies of
the minor allele based on the most probable genotype (additive genotypic
model). For completeness, logistic regression analyses of zoster case/
control status as a dichotomous phenotype was performed in PLINK25 with
the given covariates and genotypes.25
PheWAS
To determine pleiotropic effects of the SNPs associated with zoster
(rs114864815, rs114045064), we assessed a range of associated clinical
phenotypes (PheWAS) in 28 580 genotyped individuals of European
ancestry from seven different eMERGE sites with EMR-linked DNA biobanks
with Vanderbilt University.9,10
The PheWAS algorithm identified 1619 unique PheWAS ‘phenotypes’
from 6 994 816 unique dates of interaction with the EMR. Per dichotomous
phenotype, participants were grouped as a corresponding ‘case’ using
distinct ICD-9 billing codes from each participant’s records. Under the
presumption that acute diseases such as infections and infectious
complications like zoster may not be billed multiple times, a ‘case’ was a
record that had a single, valid ICD-9 code that maps to PheWAS case
group, and ‘controls’ were assigned if the participant did not have any
ICD-9 codes belonging to the exclusion code grouping corresponding for
that case. Association tests were performed using logistic regression in R
with the PheWAS package, adjusted for decade of birth, self-reported sex,
study site and the first three principal components.9,10
Other plots
The regional LD plot was created using the SNP Annotation and Proxy
Search software.26 The background recombination rate was generated
from the 1000 Genomes Pilot 1 data, specifically the CEPH (Utah residents
with ancestry from northern and western Europe) sample. The dot plot of
median values by genotype was created using the summary function from
the Hmisc R statistical computing package (Web Resources).
WEB RESOURCES
1. eMERGE web site: http://www.gwas.net
2. eMERGE Coordinating Center genotyping data: http://emerge.
mc.vanderbilt.edu/genotyping-data-released
3. PheKB phenotype: http://phekb.org/phenotype/herpes-zoster
4. R package Hmisc: http://cran.r-project.org/web/packages/
Hmisc/index.html
5. R package rms: http://cran.r-project.org/web/packages/rms/
index.html
6. R package SNPRelate: https://github.com/zhengxwen/SNPRelate
7. R package PheWAS: https://knowledgemap.mc.vanderbilt.edu/
research/content/phewas-r-package
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